|
1
|
Huang C, Xu J and Li Z: Research Progress
of Cancer-associated Fibroblasts in Lung Cancer]. Zhongguo Fei Ai
Za Zhi. 23:267–273. 2020.(In Chinese). PubMed/NCBI
|
|
2
|
Marx A, Chan JK, Coindre JM, Detterbeck F,
Girard N, Harris NL, Jaffe ES, Kurrer MO, Marom EM, Moreira AL, et
al: The 2015 World health organization classification of tumors of
the thymus: Continuity and changes. J Thorac Oncol. 10:1383–1395.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu Y, Zhu Y, Bai L, Chen F, Wang J and
Guo Y: Adenocarcinomatous-predominant subtype associated with a
better prognosis in adenosquamous lung carcinoma. BMC Cancer.
20:5202020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World health
organization classification of tumors of the lung, pleura, thymus,
and heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filosso PL, Ruffini E, Asioli S, Giobbe R,
Macri L, Bruna MC, Sandri A and Oliaro A: Adenosquamous lung
carcinomas: A histologic subtype with poor prognosis. Lung Cancer.
74:25–29. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maeda H, Matsumura A, Kawabata T, Suito T,
Kawashima O, Watanabe T, Okabayashi K and Kubota I; Japan National
Hospital Organization Study Group for Lung Cancer, : Adenosquamous
carcinoma of the lung: Surgical results as compared with squamous
cell and adenocarcinoma cases. Eur J Cardiothorac Surg. 41:357–361.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forde PM, Spicer J, Lu S, Provencio M,
Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson
SJ, et al: Neoadjuvant nivolumab plus chemotherapy in resectable
lung cancer. N Engl J Med. 386:1973–1985. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Mai W, Jiang W and Geng Q:
Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol.
10:5945582020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang J, Wang Y, Gao Y, Sugimura H,
Minervini F, Uchino J, Halmos B, Yendamuri S, Velotta JB and Li M:
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell
lung cancer: A systematic review and meta-analysis. Transl Lung
Cancer Res. 11:277–294. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Detterbeck FC, Boffa DJ, Kim AW and Tanoue
LT: The Eighth Edition lung cancer stage classification. Chest.
151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huber RM, Kauffmann-Guerrero D, Hoffmann H
and Flentje M: New developments in locally advanced nonsmall cell
lung cancer. Eur Respir Rev. 30:2002272021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin
X, Ma X, Guo Y, Qiu S, Shao G, et al: Interim analysis of the
efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab)
combined with chemotherapy (nab-paclitaxel and carboplatin) in
potentially resectable stage IIIA/IIIB non-small cell lung cancer:
A single-arm, phase 2 trial. J Cancer Res Clin Oncol. 149:819–831.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thai AA, Solomon BJ, Sequist LV, Gainor JF
and Heist RS: Lung cancer. Lancet. 398:535–554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang N, Chen S, Guo L and Chen X: A case
report of right upper lung adenosquamous carcinoma resection
following neoadjuvant targeted therapy. Ann Palliat Med.
10:4987–4993. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brody R, Zhang Y, Ballas M, Siddiqui MK,
Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in
advanced NSCLC: Insights into risk stratification and treatment
selection from a systematic literature review. Lung Cancer.
112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang J, Zhang C and Zhong WZ: Neoadjuvant
immunotherapy for non-small cell lung cancer: State of the art.
Cancer Commun (Lond). 41:287–302. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie J, Wu X, Wu J, Huang F and Xu L:
Meta-analysis of the efficacy and safety of sintilimab for treating
advanced non-small cell lung cancer. Oncol Lett. 24:4252022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S,
Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor
(Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao M, Yao J, Wang Y, Zhao L, Li B, Li L,
Wu Z, Chen Z, Fan J and Qiu F: Two vs three cycles of neoadjuvant
sintilimab plus chemotherapy for resectable non-small-cell lung
cancer: NeoSCORE trial. Signal Transduct Target Ther. 8:1462023.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus Chemotherapy in Metastatic
Non-Small-Cell Lung Cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Expert Committee on Quality Control of
Lung Cancer, National Quality Control Center for Cancer: Expert
consensus on the pathological evaluation of neoadjuvant therapy
efficacy for non-small cell lung cancer. Zhonghua Bing Li Xue Za
Zhi. 50:1002–1007. 2021.(In Chinese). PubMed/NCBI
|
|
23
|
Song P, Zhang J, Shang C and Zhang L:
Curative effect assessment of immunotherapy for non-small cell lung
cancer: The ‘blind area’ of Immune Response Evaluation Criteria in
Solid Tumors (iRECIST). Thorac Cancer. 10:587–592. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fleming CA, McCarthy K, Ryan C, McCarthy
A, O'Reilly S, O'Mahony D, Browne TJ, Redmond P and Corrigan MA:
Evaluation of discordance in primary tumor and lymph node response
after neoadjuvant therapy in breast cancer. Clin Breast Cancer.
18:e255–e261. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei J, Xiang J, Hao Y, Si J, Gu X, Xu M
and Song Z: Clinical outcomes of immune checkpoint inhibitor
therapy for advanced lung adenosquamous carcinoma. J Thorac Dis.
15:260–269. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li C and Lu H: Adenosquamous carcinoma of
the lung. Onco Targets Ther. 11:4829–4835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Gao Z, Zhang C, Liu X, Liu Z, Lin
X, Qian B, Jin F, Shao G and Yang Z: Asynchrony of primary tumor
and mediastinal lymph nodes response after neoadjuvant
immunotherapy plus chemotherapy in a patient with stage IIIA
non-small-cell lung cancer: A case report. Anticancer Drugs.
33:e784–e788. 2022. View Article : Google Scholar : PubMed/NCBI
|
